# Larimar Therapeutics, Inc. (LRMR) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Larimar Therapeutics, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/LRMR/mda/fy2025/): filed 2026-03-19; accession 0001193125-26-115878 (https://www.sec.gov/Archives/edgar/data/1374690/000119312526115878/lrmr-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/LRMR/mda/fy2024/): filed 2025-03-24; accession 0000950170-25-043925 (https://www.sec.gov/Archives/edgar/data/1374690/000095017025043925/lrmr-20241231.htm)
- [FY 2023 MD&A](/company/LRMR/mda/fy2023/): filed 2024-03-14; accession 0000950170-24-031529 (https://www.sec.gov/Archives/edgar/data/1374690/000095017024031529/lrmr-20231231.htm)
- [FY 2022 MD&A](/company/LRMR/mda/fy2022/): filed 2023-03-14; accession 0000950170-23-007855 (https://www.sec.gov/Archives/edgar/data/1374690/000095017023007855/lrmr-20221231.htm)
- [FY 2021 MD&A](/company/LRMR/mda/fy2021/): filed 2022-03-25; accession 0000950170-22-004637 (https://www.sec.gov/Archives/edgar/data/1374690/000095017022004637/lrmr-20211231.htm)

Back to /company/LRMR/